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Abstract
Background: Current in vitro allergen- specific IgE (sIgE) detection assays measure 
IgE against allergen extracts or molecules in a single- or multiplex approach. Direct 
comparisons of the performance of such assays among young children with common 
presentations of allergic diseases regardless of sensitization status are largely missing.
Objectives: The aim of this study was a comparison of the analytical and diagnos-
tic performance for common clinical questions of three commonly used technologies 
which rely upon different laboratory methodologies among children of the All Age 
Asthma (ALLIANCE) cohort (clinicaltrials.gov: NCT02496468).
Methods: Sera from 106 paediatric study participants (mean age 4 years) were as-
sessed for the presence of sIgE by means of the ImmunoCAP™ sx1 and fx5 mixes, the 
ImmunoCAP ISAC™ 112 microarray and a Euroline™ panel.
Results: Total and negative concordance was high (>82%– >89%), while positive con-
cordance varied considerably (0%– 100%) but was also >50% for the most common 
sensitizations analysed (house dust mite and birch). All three test systems showed 
good sensitivity and specificity (AUC consistently > 0.7). However, no significant 
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1  |  INTRODUC TION
In vitro test systems which detect allergen- specific IgE (sIgE) are 
a mainstay of diagnostic work- up in allergology, detecting sensiti-
zation and confirming clinically suspected allergies and/or cross- 
reactivities. They may guide treatment with regard to avoidance 
of allergens, application of seasonally directed anti- allergic therapy 
and allergen immunotherapy (AIT). Sensitization patterns have been 
shown to predict the development of allergic diseases, disease pro-
gression and severity.1- 8
A multitude of laboratory methodologies to detect allergen sIgE 
are currently available, including multiplex approaches9,10 which are 
particularly attractive in paediatric allergology since they require 
lower blood sample volumes for a comprehensive allergy work- up as 
compared to singleplex tests. Yet, the “by- product” is the detection 
of sensitizations against allergens whose clinical relevance remains 
unclear. Selection of a sandwich immunoassay versus a semiquanti-
tative immunoblot- versus a chip (microarray)- based assay influences 
the number of allergens which can be assessed simultaneously but 
may also influence analytical and diagnostic performance. Testing 
for sIgE against allergen extracts is favoured in cases of mono- or 
oligo- sensitization, low clinical risk and highly abundant and/or sta-
ble allergens. Allergenic molecules (components) on the other hand 
are preferred among polysensitized patients who are suspected to 
be sensitized against low abundance or labile proteins in allergen 
sources/extracts or among oligosensitized patients with the aim to 
differentiate between genuine sensitizations and cross- reactivity.11 
Systematic comparisons of the analytical and clinical performance of 
CS), and Thermo Fisher Scientific, Sweden 
(to CS) as well as by the Foundation 
for Pathobiochemistry and Molecular 
Diagnostics.
differences with regard to identifying sIgE sensitizations associated with symptoms 
in children with suspected pollen- or dust- triggered wheeze or presenting with symp-
toms of allergic rhinoconjunctivitis or food allergy were detected. Extending the num-
ber of allergens did not change the similar performance of the three assay systems.
Conclusion and Clinical Relevance: Among young children, the three sIgE assays 
showed good analytical and diagnostic concordance. Our results caution that the 
identification of larger numbers of sensitizations by more comprehensive multiplex 
approaches may not improve the clinical utility of sIgE testing in this age group.
K E Y W O R D S
allergen sIgE, analytical performance, diagnostic performance, in vitro allergy diagnosis, 
molecular allergology
G R A P H I C A L  A B S T R A C T
Among 106 young children (mean age 4 years) of the All Age Asthma (ALLIANCE) cohort, ImmunoCAP™ sx1 and fx1 mixes, the ImmunoCAP 
ISAC™ 112 microarray, and a Euroline™ panel showed good analytical and diagnostic concordance in four common clinical scenarios. Our 
results caution that the identification of larger numbers of sensitizations by more comprehensive multiplex approaches may not improve 
clinical utility of sIgE testing in this age group.
Key Messages
• Sera from children of the ALLIANCE cohort were as-
sessed for the presence of allergen sIgE.
• ImmunoCAP™ mixes, ImmunoCAP ISAC™ 112 and a 
Euroline™ panel showed good analytical and diagnostic 
concordance.
• Identification of more allergen sensitizations may not im-
prove the clinical utility of sIgE testing among children.
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different multiplex test systems, particularly among young children, 
are scarce.
Allergen challenges, particularly food challenges have a high 
specificity to detect clinically relevant sensitizations. However, they 
are work- intensive and pose a non- negligible risk of anaphylaxis. 
Thus, pre- screening of possible triggering allergens by multiplex 
assays is typically performed to narrow the number of allergens 
consecutively employed in allergen challenges. Knowledge on the 
comparative performance of different multiplex systems is thus de-
sirable to be able to gauge their interoperability.
We hypothesized that methodology and individual features of 
different allergen multiplex sIgE detection systems confer different 
utilities to their ability to detect sensitizations. We compared the per-
formance of three different assay systems in a sub- group of children 
from the paediatric arm of the ALL Age Asthma (ALLIANCE) cohort 
with regard to their ability to detect sensitizations compatible with (i) 
trigger factors eliciting respiratory symptoms as reported by the pa-
rental questionnaire (pollen or dust respectively) or (ii) allergic diseases 
as per symptoms or doctors’ diagnoses (allergic rhinoconjunctivitis or 
food allergy) typically triggered by allergen exposure (i.e. aeroallergens 
or food allergens). Sera were therefore tested for the presence of aller-
gen sIgE by the ImmunoCAP™ (sx1 and fx5 allergen extract mixes), the 
Euroline™ (extract- and component- based immunoblot), as well as the 
ImmunoCAP ISAC™ 112 (ISAC, component- based microarray).
2  |  METHODS
2.1  |  Ethics approval and consent to participate
The study protocol for the ALLIANCE cohort was prepared accord-
ing to the Declaration of Helsinki and CONSORT guidelines (http://
www.conso rt- state ment.org/) and was approved by the lead ethics 
committee (University of Lübeck, Ethics Committee, Ratzeburger 
Allee 160, 23538 Lübeck, Germany) and the local ethics committees. 
The paediatric arm of the ALLIANCE asthma cohort was registered 
at clinicaltrials.gov on July 14, 2015 (NCT02496468). Informed con-
sent for the children was given by either parent or caretaker if aged 
<8 years, and additionally by the child if ≥8 years.
2.2  |  Subjects
Serum samples from 82 children with asthma or wheeze (cases, 
77.4%) and 24 children without recurrent asthma or wheeze 
(controls, 22.6%) were obtained from young participants of the 
ALLIANCE cohort, a prospective, multicentre- based cohort of 
children with wheeze and children, adolescents and adults with 
asthma as well as healthy controls.12 Children are recruited into the 
ALLIANCE cohort if parents have reported ≥2 episodes of wheeze 
(children < age 6 years) or according to modified GINA (children > age 
6 years). Acute illness and chronic lung disease other than asthma/
wheeze are the most pertinent exclusion criteria. These apply simi-
larly to controls which may exhibit atopic comorbidities, that is al-
lergic rhinoconjunctivitis and food allergy in controls but no asthma 
or wheezy episodes.12 For the analysis presented here, we included 
all children having received ImmunoCAP™ sx1/fx5 (mixes of aeroal-
lergens and food allergens, respectively, see "Detection of allergen 
sIgE" and also Table S1 and S2 measurement at the doctor's discre-
tion in addition to Euroline™ and ImmunoCAP ISAC™ 112 analyses 
which were performed for all participants.
2.3  |  Clinical definitions
In addition to the clinical definitions of “recurrent wheeze” and 
“asthma” defined as above, we resorted to defined clinical definitions 
derived from questionnaires12 as follows: trigger factors for “wheez-
ing symptoms” were identified by parent- filled questionnaires on 
dust, pollen, animal dander, or food triggering wheezing “ever” or “in 
the past 12 months.” Food allergy was defined as experiencing food 
as a trigger factor for wheeze “ever” or “in the past 12 months” or 
specific symptoms suggestive of an allergic reaction to food (21 spe-
cific questions referring to skin or gastrointestinal reactions, ocular 
or general (malaise, syncope, allergic shock) symptoms upon food 
ingestion) as per the questionnaire, or doctor's diagnosis of food al-
lergy. Allergic rhinoconjunctivitis was defined as itchy eyes or nose 
“ever” or “in the past 12 months” as per the questionnaire or doctor's 
diagnosis of hay fever.
2.4  |  Detection of allergen sIgE
For each patient, the presence of specific IgE antibodies to aeroaller-
gens and food allergens was examined using three independent test 
platforms: ImmunoCAP™, ISAC (both by Thermo Fisher Scientific) 
and Euroline™ (Euroimmun), according to the manufacturers’ in-
structions. ImmunoCAP™ is an extract- and single component- based 
assay system presenting results in kU/L (calibrated against the WHO 
Standard for IgE). We used two premixed assays with extracts from 
14 allergen sources in total. The mix sx1 (not available in every coun-
try) contains eight aeroallergens (d1, e1, e5, g6, g12, m2, t3, w6), 
the mix fx5 comprises six food allergens (f1, f2, f3, f4, f13, f14). In 
case of a positive result, all included allergens were tested individu-
ally for this sample to confirm and define the specific sensitization. 
The ISAC is a multiplex microarray including in total 112 defined 
allergen components from 51 allergen sources, of which only food 
and aeroallergens (pollen, mite and other aeroallergens) were taken 
into account in this study (99 components from 45 sources). It is a 
manual, semiquantitative method with results given in ISU- E. The 
Euroline™ assay is a semiquantitative multiplex immunoblot, which, 
in our study, tested a total of 22 allergen extracts and 14 compo-
nents. The results were calibrated by using the three indicator bands 
on each strip and are presented in kU/L.
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For additional details regarding allergens and specific al-
lergen sources included in a given test system, please consult 
Supplementary Information and Table S1 and S2.
2.5  |  Data processing and statistical analyses
We used two thresholds for positivity for each test system: thresh-
old 1 (analytical relevance) was defined as a sIgE ≥ 0.35 kU/L for 
ImmunoCAP™ sx1/fx5 and Euroline™ (Class 1) and ≥0.3 ISU/L for ISAC 
(lowest threshold for positivity). Threshold 2 (clinical relevance, used 
in the ALLIANCE cohort) was defined as ≥0.7 kU/L for ImmunoCAP™ 
sx1/fx5 and Euroline™ (Class 2), and ≥1.0 ISU/L for ISAC (moderate 
positivity). A test result was considered positive for a specific aller-
gen when the concentration of any related extract or component ex-
ceeded the predefined threshold.
We calculated the overall concordance by dividing the number of 
samples with three equal test results by all 106 samples. Accordingly, 
positive and negative concordance represent the percentages of samples 
with three positive and negative test results among all samples tested 
positive and negative by at least one kit respectively. The comparisons 
of the test results were made using several measures, including the per-
centage of positive tests, percentage of negative tests, overall, positive, 
and negative concordance, sensitivity, specificity, negative predictive 
value (NPV), positive predictive value (PPV) and sensitization rate.
Two of the assay types (ISAC, Euroline™) cover more than one 
component for some allergen sources. We thus tested the following 
approaches: (i) either the sum of all allergen sIgE for each source 
or (ii) only the allergen with the highest response (maximum sIgE 
response) was considered. Our results showed no differences be-
tween the two approaches, so we opted to utilize the latter option 
within this publication (maximum sIgE response to any given allergen 
source).
For comparisons between the three analysis platforms with re-
gard to defined clinical outcomes, we used the following approaches: 
first, we included only those allergens (only pollen allergens, only 
mite allergens, all aeroallergens (i.e. including pollen and mite aller-
gens as well as assay- specific animal, mould and cockroach allergens, 
depending on the assay), or all food allergens) that are common to all 
three assay systems (Table 1). In a separate analysis, we included all 
allergens of a specific allergen group (as in the first approach) avail-
able in any of the test systems for comparisons (Table S1 and S2).
Diagnostic performance was illustrated by means of ROC curves 
by plotting the true- positive rate against the false- positive rate at 
different thresholds of specific allergen sIgE concentrations for the 
following determinants 1 = only pollen allergens, 2 = only mite aller-
gens, 3 = all aeroallergens, 4 = all food allergens with the correspond-
ing clinical outcomes: (i) the presence of wheezing symptoms upon 
trigger factor pollen defined per questionnaire, (ii) the presence of 
wheezing symptoms upon trigger factor dust defined per question-
naire, (iii) the presence of symptoms of or doctor's diagnosed aller-
gic rhinoconjunctivitis, (iv) the presence of symptoms of or doctor's 
diagnosed food allergy. Comparison across systems was performed 
by assessing the area under the ROC curves (AUC). We ran a global 
ANOVA to detect differences in the diagnostic performance be-
tween all three test systems followed by bootstrapping with 10,000 
bootstrap replications on the difference between each two AUC 
values. To assess the effect of one threshold over the other, or of 
considering individual allergens over all allergens, we either ran a 
McNemar's test (considering the paired nature of the data) or a bi-
nomial test between the two resulting 2x2 contingency tables which 
show the discrepancies between two given scenarios for each test. 
A p- value <.05 was considered as a statistically significant difference 
between both scenarios. We adjusted all p- values for age by stratifi-
cation and for multiple testing according to the stepdown algorithm. 
Between the assays, any significance is related to the comparison of 
the ROC curves.
All computations were performed with the software R ver-
sion 3.5.3 using the packages "openxlsx," "memisc," "surveydata," 
"survival," "ggplot2," "reshape2," "plyr," "dplyr," "doBy," "compare-
Groups," "Hmisc," "VennDiagram," "gridExtra," "plotROC," "pROC," 
"lsr," "caret," "xtable," "extrafont" and "boot."
3  |  RESULTS
3.1  |  Patient characteristics
Participants in this analysis had a mean age of 4 years (range 
0– 16 years), with the majority (69.8%) being <6 years of age. Almost 
two- thirds of all children were male (61.3%; Table 2). Cases and 
controls did not differ significantly in gender but cases were signifi-
cantly younger (mean age 3 years) than controls (mean age 6 years, 
p = .001). Both groups did not differ significantly in doctor's diag-
noses of atopic dermatitis or food allergy. Cases, however, had sig-
nificantly higher rates of allergic rhinoconjunctivitis (19.5% vs. 0%, 
p = .02). They also had higher percentages of 1st degree relatives 
with asthma compared to controls (53.1%, 48/78 cases; 25.0%, 6/24 
controls). 30.9% (25/81) of cases reported use of inhaled corticos-
teroids (ICS) use in the past four weeks. 41.2% (21/51) had ever re-
ceived systemic steroids at least once and 23.0% (17/74) in the past 
12 months. As per the use of salbutamol (a short- acting β2 agonist), 
patients reported a fairly high number of exacerbations in the past 
12 months (82.9%). 25.6% of cases had necessitated an emergency 
room visit and half of all patients had already been hospitalized for 
a wheezy episode (50.0%) yet most did not require oxygen supple-
mentation (61.0%; Table 2). The most significant parental reported 
trigger factor for wheeze was pollen (20/82), followed by dust 
(14/82), animals (6/82) and food (5/82; Table 2). At threshold 2 but 
not at threshold 1 cases displayed significantly higher sensitization 
rates determined by Euroline™ than controls for comparable and all 
allergens (Table 3), differences being significant for threshold 2 also 
for the subgroup of pollen allergens, mite allergens, all aeroallergens 
and all food allergens (data not shown).
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3.2  |  Qualitative concordance
Overall, the concordance of positive results of the comparable al-
lergens between the three test systems depended on the thresh-
old used to define positivity. When resorting to threshold 1 (see 
methods) 29/49 positive results were identified by all three test 
systems (Figure 1A). Euroline™ identified the highest number 
of positive samples (41.5% of all positive samples), while 31.1% 




ISAC™ 112 Allergen source
Aeroallergens
d1 d1 Der.p.1 House dust mite
d1 d1 Der.p.2 House dust mite
d1 d1 Der.p.10 House dust mite
e1 e1 Fel.d.1 Cat dander
e1 e1 Fel.d.2 Cat dander
e1 e1 Fel.d.4 Cat dander
e5 e2 Can.f.1 Dog dander
e5 e2 Can.f.2 Dog dander
e5 e2 Can.f.3 Dog dander
e5 e2 Can.f.5 Dog dander
m2 m2 Cla.h.8 Cladosporium
t3 t3 Bet.v.1 Common silver 
birch
t3 t3 Bet.v.2 Common silver 
birch
t3 t3 Bet.v.4 Common silver 
birch
w6 w6 Art.v.1 Mugwort
w6 w6 Art.v.3 Mugwort
Food allergens
f1 f1 Gal.d.1 Egg white
f1 f1 Gal.d.2 Egg white
f1 f1 Gal.d.3 Egg white
f2 f2 Bos.d.4 Milk
f2 f2 Bos.d.5 Milk
f2 f2 Bos.d.6 Milk
f2 f2 Bos.d.8 Milk
f2 f2 Bos.d. Lactoferrin Milk
f3 f3 Gad.c.1 Fish (cod)
f4 f4 Tri.a.14 Wheat
f4 f4 Tri.a.19.0101 Wheat
f4 f4 Tri.a.aA.TI Wheat
f13 f13 Ara.h.1 Peanut
f13 f13 Ara.h.2 Peanut
f13 f13 Ara.h.3 Peanut
f13 f13 Ara.h.6 Peanut
f13 f13 Ara.h.8 Peanut
f13 f13 Ara.h.9 Peanut
f14 f14 Gly.m.4 Soybean
f14 f14 Gly.m.5 Soybean
f14 f14 Gly.m.6 Soybean
TA B L E  1  Comparable aeroallergens 
and food allergens across all three in vitro 
diagnostic assays
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TA B L E  2  Population's characteristics
All Asthma+wheeze Controls
p overalln = 106 n = 82 n = 24
Age 4.39 ± 3.32 3.71 ± 2.92 6.71 ± 3.62 .001
Age group:
0– 6 years 74 (69.8%) 63 (76.8%) 11 (45.8%) .008
>6 years 32 (30.2%) 19 (23.2%) 13 (54.2%)
Gender
Female 41 (38.7%) 31 (37.8%) 10 (41.7%) .918
Male 65 (61.3%) 51 (62.2%) 14 (58.3%)
Atopic dermatitis
No 87 (82.1%) 64 (78.0%) 23 (95.8%) .067
Yes 19 (17.9%) 18 (22.0%) 1 (4.2%)
Food allergy
No 96 (90.6%) 72 (87.8%) 24 (100%) .112
Yes 10 (9.4%) 10 (12.2%) 0 (0.00%)
Allergic rhinoconjunctivitis
No 90 (84.9%) 66 (80.5%) 24 (100%) .020
Yes 16 (15.1%) 16 (19.5%) 0 (0.00%)
Trigger pollen
No 86 (81.1%) 62 (75.6%) 24 (100%) .006
Yes 20 (18.9%) 20 (24.4%) 0 (0.00%)
Trigger dust
No 92 (86.8%) 68 (82.9%) 24 (100%) .036
Yes 14 (13.2%) 14 (17.1%) 0 (0.00%)
Trigger animal
No 100 (94.3%) 76 (92.7%) 24 (100%) .333
Yes 6 (5.7%) 6 (7.3%) 0 (0.00%)
Trigger food
No 101 (95.3%) 77 (93.9%) 24 (100%) .586
Yes 5 (4.7%) 5 (6.1%) 0 (0.00%)
Asthma in 1st degree relative
No 56 (53.3%) 38 (46.9%) 18 (75%) .029
Yes 49 (46.7%) 43 (53.1%) 6 (25%)
Allergic rhinoconjunctivitis in 1st degree relative
No 37 (36.3%) 30 (38.5%) 7 (29.2%) .558
Yes 65 (63,7%) 48 (61.5%) 17 (70.8%)
Eczema in 1st degree relative
No 69 (69.7%) 50 (65.8%) 19 (82.6%) .201
Yes 30 (30.3%) 26 (34.2%) 4 (17.4%)
ICS use in the past 4 weeks
No 80 (76.2%) 56 (69.1%) 24 (100%) .004
Yes 25 (23.8%) 25 (30.9%) 0 (0.00%)
Systemic steroid use ever
No 35 (50.0%) 30 (58.8%) 5 (26.3%) .02
Once 8 (11.4%) 6 (11.8%) 2 (10.5%)
More than once 27 (38.6%) 15 (29.4%) 12 (63.2%)
(Continues)
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Results changed when defining a more stringent threshold 2 (see 
methods). The overall number of positive results was reduced to 39, 
of which 27 were identified by all three test systems (Figure 1B). This 
more stringent threshold led to ImmunoCAP™ sx1/fx5 identifying 
the highest percentage of positive samples (identifying 34.0% test 
samples as positive), followed by Euroline™ (28.3%) and ISAC (27.4%; 
Figure 1D).
Similarly, upon assessment of qualitative positive concordance 
for individual allergens, an increase in threshold for positivity led to 
important changes. Resorting to the lower threshold, ImmunoCAP™ 
sx1/fx5 showed the highest percentage of positive results for seven 
out of 12 comparable allergens. Euroline™ identified the highest per-
centage of positive samples for two out of 12 comparable allergens 
and ISAC showed the highest percentage of positive results for one 
out of 12 allergens (Figure 1E). Following application of the higher 
threshold, ImmunoCAP™ sx1/fx5 showed the highest percentage of 
positive results for nine allergens. ISAC remained the test system 
identifying the highest percentage of positive samples for peanut, 
and Euroline™ did not detect the highest percentage of positive sam-
ples for any comparable allergen (Figure 1F).
Overall, negative and positive concordance for all compara-
ble allergens following application of the lower or higher positivity 
threshold is shown in Figure S1. Overall and negative concordances 
were uniformly high (at least 82%, regardless of threshold). Positive 
concordance was, however, more variable ranging between 0% 
(Cladosporium and wheat at both thresholds; dog dander and soy-
bean at higher threshold) and 100%; the latter in the case of cod 
where one single positive sample was detected by all three test 
systems (Figure S1). Common silver birch and house dust mite, the 
allergens with the highest overall positive detection rates, showed 
comparatively high positive concordance (>50%) at both thresholds. 
All other allergens showed comparatively poor positive concordance 
(<50%) for both thresholds.
3.3  |  Identifying pollen sensitization triggering 
wheezing symptoms
In order to compare the diagnostic performance of the three test sys-
tems, we examined four common scenarios according to the allergenic 
source suspected by their parents of triggering allergic symptoms, 
that is, young children who present with allergic symptoms of which 
the allergen triggers are at present unknown. We calculated sensitiv-
ity and specificity (plotted as ROC curves), as well as positive (PPV) 
and negative predictive values (NPV) for each of these scenarios.
As the first clinical scenario, we chose children whose par-
ents reported wheezy symptoms triggered by pollen exposure 
(questionnaire- based item: trigger factor pollen “ever” or “within 
the last 12 months” for wheezing symptoms, positive for 20 of all 
106 children). As determinants, we assessed sIgE values above the 
threshold for pollen allergens (defined in Tables 1, S1, Supplementary 
Information). Neither of the three assay systems displayed significant 
superiority for NPV, PPV, sensitivity or specificity for comparable or all 
pollen sensitizations, regardless of the thresholds used (Figure 2A- D).
Changing the threshold for positivity from threshold 1 to thresh-
old 2 did not lead to significant changes of sensitivity, specificity, 
All Asthma+wheeze Controls
p overalln = 106 n = 82 n = 24
Systemic steroid use in the past 12 months
No 84 (79.2%) 57 (77.0%) 27 (84.4%) .551
Yes 22 (20.8%) 17 (23.0%) 5 (15.6%)
SABA use in the past 12 months
No 38 (35.8%) 14 (17.1%) 24 (100%) <.001
Yes 68 (64.2%) 68 (82.9%) 0 (0.00%)
Emergency room consultation for wheeze in the past 12 months
No 85 (80.2%) 61 (74.4%) 24 (100%) .003
Yes 21 (19.8%) 21 (25.6%) 0 (0.00%)
Hospitalization for wheeze (ever)
No 65 (61.3%) 41 (50.0%) 24 (100%) <.001
Yes 41 (38.7%) 41 (50.0%) 0 (0.00%)
Supplemental oxygen for wheeze (ever)
No 74 (69.8%) 50 (61.0%) 24 (100%) .001
Yes 32 (30.2%) 32 (39.0%) 0 (0.00%)
Note: Basic demographic and clinical characteristics of the study cohort. Sera from 106 children from the ALLIANCE cohort were assessed for 
allergen sIgE by means of three commercially available test systems. Thresholds were ≥0.35 kU/L (threshold 1) and ≥0.7 kU/L (threshold 2) for 
ImmunoCAP™ and Euroline™ and ≥0.3 ISU/L (threshold 1) and ≥1.0 ISU/L (threshold 2) for ImmunoCAP ISAC™ 112.
Abbreviations: ICS, Inhaled corticosteroids; SABA, Short- acting β2 agonists.
TA B L E  2  (Continued)
8  |    SKEVAKI Et Al.
Asthma+wheeze Controls p overall
ImmunoCAP™
Threshold 1
All allergens 33 (40.2%) 4 (16.7%) <.001
Comparable allergens 33 (40.2%) 3 (12.5%) <.001
Threshold 2
All allergens 33 (40.2%) 3 (12.5%) <.001
Comparable allergens 33 (40.2%) 3 (12.5%) <.001
Euroline
Threshold 1
All allergens 42 (51.2%) 12 (50.0%) .865
Comparable allergens 37 (45.1%) 7 (29.2%) .209
Threshold 2
All allergens 30 (36.6%) 3 (12.5%) <.001
Comparable allergens 27 (32.9%) 3 (12.5%) .004
ImmunoCAP ISAC™ 112
Threshold 1
All allergens 33 (40.2%) 4 (16.7%) .011
Comparable allergens 31 (37.8%) 2 (8.3%) <.001
Threshold 2
All allergens 28 (34.1%) 3 (12.5%) .002
Comparable allergens 27 (32.9%) 2 (8.3%) <.001
Note: Thresholds for the determination of overall sensitization rates were ≥0.35 kU/L (threshold 1) 
and ≥0.7 kU/L (threshold 2) for ImmunoCAP™ and Euroline™ and ≥0.3 ISU/L (threshold 1) and ≥1.0 
ISU/L (threshold 2) for ImmunoCAP ISAC™ 112.
TA B L E  3  Overall sensitization rates
F I G U R E  1  Analytical performance. Venn diagram and percentage of positive samples/assay for threshold 1 = ≥0.35 kU/L for 
ImmunoCAP™ and Euroline™ (Class 1), and ≥0.3 ISU/L for ImmunoCAP ISAC™ 112 (A, C) and for threshold 2 = ≥0.7 kU/L for ImmunoCAP™ 
and Euroline™ (Class 2) and ≥1,0 ISU/L for ImmunoCAP ISAC™ 112 (B, D); percentage of positive samples for comparable allergens only, for 
threshold 1 (E) and threshold 2 (F)
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NPV or PPV, except for the Euroline™ when assessing all pollen al-
lergens included in the Euroline™ (p = .001, 2B vs. 2D).
As expected, enlarging the spectrum of allergens significantly 
increased sensitivity at the expense of specificity and NPV at the 
expense of PPV for all test systems (“comparable pollen allergens” 
vs. “all pollen allergens”, Figure 2A vs. B, C vs. D; for details refer 
to Supplementary Information, Tables 1, S1). This was indepen-
dent of the threshold used (p < .001/p = .001/.016 at threshold 
1, p = .008/.002/.031 at threshold 2) for Euroline™ versus ISAC/
ImmunoCAP™ sx1.
Considering only pollen allergens comparable across all three test 
systems, the ImmunoCAP™ sx1 test system showed significantly better 
performance for prediction of wheezing symptoms triggered by pollen 
exposure than ISAC but not compared to Euroline (Figure 2E, areas 
under the ROC curves (AUCs) for ImmunoCAP™, ISAC, Euroline™: 
0.836, 0.725 and 0.746, respectively, p = .041 for ImmunoCAP™ sx1 
vs. ISAC, p = .080 for ImmunoCAP™ sx1 vs. Euroline™). This difference 
was lost when including all pollen allergens contained in each test sys-
tem into our analysis (Figure 2F, p = .689 for ImmunoCAP™ sx1 vs. 
ISAC, p = .097 for ImmunoCAP™ sx1 vs. Euroline™).
3.4  |  Identifying mite allergens triggering 
wheezing symptoms
As the second scenario, we chose children whose parents re-
ported that wheezing symptoms were triggered by dust exposure 
(questionnaire- based item: trigger factor dust “ever” or “within the 
last 12 months” for wheezing, positive for 14 of all 106 children), 
comparing the detected sensitizations against comparable versus all 
mite allergens as determinants (for details refer to Supplementary 
Information, Tables 1, S1).
Again, neither of the three assay systems displayed significant 
superiority for NPV, PPV, sensitivity or specificity for comparable 
or all mite allergens, regardless of the threshold used (Figure 3A- D).
There were mild increases in PPV and decreases in sensitivity 
(associated with mild increases in specificity) when comparing the 
lower to the higher threshold, however, these changes did not reach 
statistical significance (Figure 3A- D).
Unlike the trigger factor pollen, increasing the number of mite- 
specific allergens in a given test system did not induce consistent or 
significant changes in NPV, PPV, sensitivity or specificity (Figure 3A- D).
F I G U R E  2  Negative (NPV) and positive predictive value (PPV), sensitivity and specificity for outcome respiratory symptoms, triggered 
by pollen. NPV, PPV, sensitivity and specificity for comparable pollen allergens and for all pollen allergens/assay for threshold 1 (A, B) and 
for threshold 2 (C, D). (E) ROC curves for outcomes "trigger pollen" for comparable and (F) all pollen allergens tested by the assays. For 20 of 
all 106 children, parents reported pollen as trigger for asthma/wheeze. *p < .05 for all versus comparable allergens, +p < .05 for threshold 1 
versus threshold 2, #p < .05 between assays
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AUCs of the ROC curves were the highest and significant for 
ImmunoCAP™ sx1 for both comparable and all house dust mite al-
lergens included (0.815 for ImmunoCAP™ (both comparable and 
all mite allergens) versus 0.770 and 0.768 for ISAC (p = .029/.033) 
versus .771 and .774 for Euroline™ (p = .040/.040), Figure 3E- F).
3.5  |  Identifying aeroallergen sensitization in 
children with allergic rhinoconjunctivitis
In the third scenario, we analysed children who presented with aller-
gic rhinoconjunctivitis (questionnaire- based or doctor's- diagnosed, 
positive for 16 of all 106 children), comparing the detected sensitiza-
tions against all comparable versus all aeroallergens as determinants 
(for details refer to Supplementary Information, Tables 1, S1).
We did not observe any significant differences between the 
three assays’ diagnostic performance in detecting clinically rele-
vant aeroallergen sensitizations (NPV, PPV, sensitivity, specificity, 
Figure 4A- D).
Increasing stringency by moving from threshold 1 to threshold 
2 consistently improved PPV and specificity for all three assays, yet 
these changes only attained statistical significance for the Euroline™ 
(Figure 4A vs. C and B vs. D, p = .031 and p = .002, for all comparable 
and all aeroallergens respectively).
Inclusion of all aeroallergens instead of only comparable aller-
gens decreased PPV and specificity for all three assays for both 
thresholds but this change was only statistically significant for the 
Euroline™ at the lower threshold (Figure 4A vs. B, p = .031).
Furthermore, we could not detect any significant differences be-
tween the three assays in terms of predicting the outcome allergic rhi-
noconjunctivitis (questionnaire- based items: “itchy nose,” “itchy eyes,” or 
“itchy nose and eyes” “ever” or “within the last 12 months” or doctor's- 
diagnosed hay fever, determinants: all comparable or all aeroallergens in 
the three test systems) by ROC analyses of aeroallergens (Figure 4E- F).
3.6  |  Identifying food allergen sensitization in 
children with food allergy
Finally, in the fourth scenario, we analysed the diagnostic perfor-
mance in children with food allergy (questionnaire- based items: 
triggering food(s) for wheeze or specific symptoms suggestive of an 
allergic reaction to food, both “ever” or “within the past 12 months” 
or doctor's- diagnosed food allergy, positive for 5 of all 106 children), 
F I G U R E  3  Negative (NPV) and positive predictive value (PPV), sensitivity and specificity for outcome respiratory symptoms, triggered 
by dust. NPV, PPV, sensitivity and specificity for comparable mite allergens and for all mite allergens/assay for threshold 1 (A, B) and for 
threshold 2 (C, D). (E) ROC curves for outcomes "trigger dust" for comparable and (F) all mite allergens tested by the assays. For 14 of all 106 
children, parents reported dust as trigger factor for asthma/wheeze. #p < .05 between assays
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assessing as determinants sIgE against comparable versus all food al-
lergens (for details refer to Supplementary Information, Tables 1, S2). 
In these children, the overall diagnostic performance for determin-
ing sensitization against food allergens was similar with no consistent 
and significant superiority detected for any system (Figure 5A- D).
Increasing the threshold consistently increased PPV and spec-
ificity at the expense of sensitivity, however, these changes were 
statistically significant only for the Euroline™ for comparable and all 
food allergens (both p < .001, Figure 5A vs. C and B vs. D).
Increasing the number of allergens consistently resulted in de-
creased PPV and specificity, which was statistically significant for 
the Euroline™ and the ISAC at the lower threshold (Figure 5A vs. B, 
p < .001 and p = .031) and for the ISAC at the higher threshold also 
(Figure 5C vs. D, p = .016).
AUCs of ROC curves for sensitivity and specificity also showed no 
statistically significant differences in predicting food allergy (Figure 5E- F).
4  |  DISCUSSION
In the analyses presented here, we compared the analytical and di-
agnostic performance of three test systems to detect sIgE in allergen 
mixes and in multiplex assays respectively. Although the three sys-
tems are based on different laboratory methodologies, our results 
show good and comparable overall and negative concordance and 
good positive concordance for the most common sensitizations 
found in our cohort (dust mite and birch). Similarly, the diagnostic 
performance of all tests was largely comparable regarding typical 
clinical scenarios such as the identification of clinically relevant 
food and aeroallergen sensitization. Regarding the outcomes “trig-
ger factor pollen” and “trigger factor dust” where significant differ-
ences could be observed between the ImmunoCAP™ sx1/fx5 and 
the Euroline™ versus the ISAC (pollen) and the ImmunoCAP™ sx1/
fx5 versus the Euroline™ and the ISAC (dust), these differences were 
small and most likely do not affect clinical utility. The comparatively 
larger allergen number included in the Euroline™ compared to the 
ISAC led to the detection of higher numbers of sensitization com-
pared to the ImmunoCAP™ sx1/fx5. These differences, however, did 
not consistently identify more sensitizations associated with clinical 
symptoms, questioning the utility of larger allergen panels and/or 
molecular- based methodologies in this age group.
Allergen sIgE screening assays are a mainstay of paediatric aller-
gology because trigger factors for young children's allergic symptoms 
are often more difficult to discern than in older children or adults 
F I G U R E  4  Negative (NPV) and positive predictive value (PPV), sensitivity and specificity for outcome allergic rhinoconjunctivitis. NPV, 
PPV, sensitivity and, specificity for comparable aeroallergens and for all aeroallergens/assay for threshold 1 (A, B) and for threshold 2 
(C, D). (E) ROC curves for outcome "allergic rhinoconjunctivitis" for comparable and (F) all aeroallergens tested by the assays. Sixteen of all 
106 children with asthma/wheeze had allergic rhinoconjunctivitis. *p < .05 for all versus comparable allergens, +p < .05 for threshold 1 versus 
threshold 2
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and these assays require low blood volumes per number of detect-
able allergens. Whilst extended, molecular- based screening systems 
are clearly useful in an epidemiological context where patterns of 
sensitization have been shown to be associated with trajectories of 
disease,1- 6 their utility in clinical practice in young children remains 
unclear. Component- resolved diagnostics can provide information 
which cannot be obtained by extract- based assay systems.13- 15 
However, depending on their composition, component- resolved 
assays may miss minor allergen specificities that are diagnostically 
relevant for individual patients compared to more comprehensive 
extract- based assays. Indeed, when we investigated which assay 
showed the most positive samples for any single allergen, the 
ImmunoCAP™ sx1/fx5 outperformed the Euroline™ and the ISAC, 
regardless of the threshold (Figure 1E,F). Published comparisons 
of sIgE assays often focus on analytical performance13- 17 which do 
not provide information on clinical utility. Available diagnostic per-
formance studies typically include patients characterized by a spe-
cific sensitization and symptom profile.18,19 In line with our findings, 
Wang et al. showed that the predictive values of allergen sIgE tests 
vary largely, depending on the allergen analysed.20 Similarly, Griffiths 
et al. found that the ImmunoCAP™ performed better than the ISAC 
for single allergens but also on a diagnostic level analytically with 
regard to the identification of anaphylaxis. The ISAC outperformed 
the ImmunoCAP™ among patients with oral allergy syndrome.19
The uniqueness of our study lies in (i) the inclusion of children at 
a young age, (ii) the inclusion of children regardless of sensitization 
status and/or profile and (iii) the comparison of the analytical and 
diagnostic performance of three in vitro sIgE test systems commonly 
used in research or clinical settings. Indeed, to our knowledge, our 
report is the first including the Euroline™, the ImmunoCAP™ sx1/fx5 
and the ISAC chip in a comprehensive comparative study.
Our analyses identify similar inter- assay agreement compared 
to studies by others,20 including component- resolved panel sys-
tems.13- 17,21,22 We did find that, when considering overall positive 
samples, the Euroline™ suffered from a higher background signal as 
it detected the highest number of sensitizations at threshold 1, the 
less stringent threshold, but not at threshold 2, the higher and more 
stringent threshold. Along these lines, sensitivity, specificity, NPV 
and PPV of the three test systems we compared were similar to what 
others have previously reported,19,20,23 reassuring the practicing al-
lergologist and confirming an overall good concordance.
When increasing the number of considered allergens in our anal-
yses from comparable allergens to all allergens within one assay, that 
is interrogating the value of extended (component resolved) allergen 
F I G U R E  5  Negative (NPV) and positive predictive value (PPV), sensitivity and specificity for outcome food allergy. NPV, PPV, sensitivity 
and, specificity for comparable food allergens and for all food allergens/assay for threshold 1 (A, B) and for threshold 2 (C, D). (E) ROC curves 
for outcome "food allergy" for comparable and (F) all food allergens tested by the assays. For 5 of all 106 children, parents reported food as 
trigger factor for asthma/wheeze. *p < .05 for all versus comparable allergens, +p < .05 for threshold 1 versus threshold 2
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panels, we detected up to 14 additional sensitizations with an aver-
age of four across all allergen groups and thresholds (Table S3). Yet, 
mostly, we identified non- significant decreases in PPV and specific-
ity by these changes, regardless of the clinical scenario (Figures 2– 
5, A– D). Clinical prediction of specific allergens responsible for 
triggering clinical symptoms assessed by ROC curves did also not 
improve significantly by employing more comprehensive allergen 
panels (Figures 2– 5, E– F). Rather contrary, for the association of the 
scenario of wheeze upon trigger dust with house dust mite sensiti-
zation, the extract- based ImmunoCAP™ sx1 mix outperformed both 
other more comprehensive assay systems (Figure 3F), suggesting 
that Dermatophagoides pteronyssinus (extract d1) constitutes the 
most important allergen source for clinically relevant sensitization to 
(dust) mite in our cohort. Thus, in the age group we analysed, where 
polysensitization is not common yet, the additionally identified sen-
sitizations to d2 and d4 (Euroline™) and Der f1, Der f2 and Lep d2 
(ISAC) appear to only inconsistently translate into symptoms and 
mostly seem to be “silent”.
The only exception thereof was the analysis of pollen sensitiza-
tion in the scenario of pollen- triggered wheeze where a more com-
prehensive allergen panel significantly improved PPV and specificity 
(Figure 2A vs. B, C vs. D). Grass sensitization could only be included 
in the analysis of all allergens (Figure 2B,D) but not in the analysis of 
comparable allergens (Figure 2A,C). The lack of comparable grass al-
lergens across the three test systems (Table 1 vs. S1) thus hampered 
comparability. Another possible explanation could be that children 
with grass pollen sensitization were somewhat older than children 
with dust mite sensitization or food allergy. This supports the notion 
that a larger spectrum of allergens improves diagnostics for older 
individuals, who are more likely to be polysensitized or sensitized 
against multiple allergen components of a single source but not for 
young children. However, our p- values were age- adjusted, refuting 
age as a critical confounder in these analyses.
Particularly in food allergies, the eliciting trigger factors might 
not always be clinically discernable and oral challenges thus are the 
gold standard for diagnosis. In these situations, the detection of spe-
cific sensitizations via sIgE assays can guide the selection of aller-
gens for food challenges. In that line, our results provide a firm basis, 
that neither of the three assay systems we analysed shows a distinct 
advantage in detecting sensitizations.
One important limitation of our study is that we resorted to pa-
rentally reported trigger factors and doctor's diagnosis of hay fever 
or food allergy, as indicative of clinically significant sensitizations. 
Allergen challenges similar to Käck et al.24 certainly constitute the 
gold standard for assessing diagnostic performance. However, our 
approach was not restricted to a single allergen and would have 
therefore required several challenges, which were beyond our study 
group's capacity and would have subjected our young participants to 
substantial risks. Similarly, assessing other available test systems as 
well as consideration of the Clinical Laboratory Standards Institute 
(CLSI) I/LA- 20 guideline was beyond the scope of this report.
The Euroline™ and the ISAC, which either test a mix of extracts 
and components (Euroline™) or include only components (ISAC), 
consistently detected more sensitizations than the ImmunoCAP™ 
sx1/fx5 when extending testing to all allergens from a given aller-
gen group (Table S3). Others have stressed that component- resolved 
diagnostics may increase the number of identified allergen sensiti-
zations23,25- 29 which we can corroborate by our findings (Table S3). 
However, the aforementioned studies did not address the clinical 
utility of their findings. Studies which have shown added clinical 
value for molecular allergen component- based microarrays have in-
cluded older children and did not compare to extract- based systems 
making a comparison to our results difficult.24
Our study identified lower sensitization rates (depending on test 
system, threshold and allergens included: 27%– 51% of all children 
and 33%– 51% of children with wheeze/asthma identified as sen-
sitized) (Table 3) compared to those found by Önell et al. (75% of 
all children and 100% of all asthmatic children identified as sensi-
tized). This difference is most likely due to the fact that Önell et al.23 
included an older age range but we cannot exclude that the lower 
rates of sensitization may have affected our ability to find significant 
differences in analytical and/or diagnostic performance which could 
have only been addressed by including a larger group of children. 
It is of note, that upon the use of the lower threshold for overall 
sensitization rates Euroimmun™ does not discriminate between 
asthmatics/wheezers versus controls but only achieves this discrim-
ination at the higher threshold while ImmunoCAP™ and the ISAC 
achieve such discrimination at both thresholds (Table 3). This further 
supports our choice within the ALLIANCE consortium on choosing 
the higher threshold for identifying children with atopy. Our results 
suggest, however, that among younger children where polysensiti-
zation across a multitude of allergen species is still rare, component- 
resolved sIgE test systems may not improve diagnostic performance 
in common clinical scenarios. This may be different in older, poly-
sensitized patients.27- 29 In our study population, multiplex allergen 
sIgE testing increases the risk of revealing sensitizations of unknown 
clinical significance. Thus, careful history taking, physical examina-
tion, and— in the case of suspected food allergy— standardized food 
challenges remain indispensable for personalized treatment of dif-
ferent allergic patients.
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